natgillin/translations-raw huggingface dataset:
Hæmaturi Ved hæmaturi i de øvre urinveje er der øget risiko for obstruktion af ureter. 
Haematuria In case of haematuria from the upper urinary tract, there is a risk for urethral obstruction.
Det skal De vide, før De får <lægemidler, der indeholder tranexamsyre> De må ikke få <lægemidler, der indeholder tranexamsyre>, hvis De: 
What you need to know before you are given <Tranexamic acid - containing medicinal products> Do not take <Tranexamic acid - containing medicinal products> if you:
• Hvis De får langtidsbehandling med <lægemidler, der indeholder tranexamsyre>, skal De være særligt opmærksom på ændringer i farvesynet, og om nødvendigt skal behandlingen afbrydes. 
• If you are on a long-term treatment with X, attention should be paid to possible disturbances of colour vision and if necessary the treatment should be discontinued.
Standardbehandling ved lokal fibrinolyse: 0,5 g (1 ampul med 5 ml) til 1 g (1 ampul med 10 ml eller 2 ampuller med 5 ml) tranexamsyre som langsom intravenøs injektion (= 1 ml/min.) 
Standard treatment of local fibrinolysis: 0.5 g (1 ampule of 5 ml) to 1 g (1 ampule of 10 ml or 2 ampules of 5 ml) tranexamic acid by slow intravenous injection (= 1 ml/minute) two to three times daily 2.
<Lægemidler, der indeholder tranexamsyre> indeholder tranexamsyre, som tilhører en gruppe lægemidler, der kaldes hæmostatika med antifibrinolytisk virkning. 
<Tranexamic acid - containing medicinal products> contains tranexamic acid which belongs to a group of medicines called antihaemorragics; antifibrinolitics, aminoacids.
Derfor frarådes amning. 
Therefore, breastfeeding is not recommended.
1.073 børn var inkluderet, og heraf fik 631 tranexamsyre. 
Literature review identified 12 efficacy studies in paediatric cardiac surgery which have included 1073 children, 631 having received tranexamic acid.
Dosis i.v. 
Dose IV
Der er set tilfælde af kramper i forbindelse med behandling med tranexamsyre. 
Cases of convulsions have been reported in association with tranexamic acid treatment.
Administration <Lægemidler, der indeholder tranexamsyre> må kun gives langsomt i en blodåre. 
Method of administration <Tranexamic acid - containing medicinal products> should only be administrated slowly into a vein.
5 mg/kg 
10 mg/kg BW Every 24 hours 5 mg/kg BW
6.6 Regler for bortskaffelse <og anden håndtering> [Udfyldes nationalt] 
6.6 Special precautions for disposal and other handling [To be completed nationally]
Der er ikke gennemført studier af dosis-virkning på børn. 
No specific dose-effect study or PK study has been conducted in children.
Synsforstyrrelser herunder påvirket farvesyn 
- Visual disturbances including impaired colour vision
• Hvis De lider af kramper, bør De ikke få <lægemidler, der indeholder tranexamsyre>. 
• If you have had convulsions, <Tranexamic acid - containing medicinal products> should not be administered.
Som følge deraf bør tranexamsyre for en sikkerheds skyld ikke anvendes i første trimester, heller ikke selvom dyrestudier ikke indikerer teratogene virkninger. 
As a result, although studies in animals do not indicate teratogenic effects, as precaution for use, tranexamic acid is not recommended during the first trimester of pregnancy.
Spørg lægen eller sundhedspersonalet, hvis der er mere, De vil vide. 
- If you have any further questions, ask your doctor or nurse.
Hvis De får sygdomsforandringer i øjet, især sygdomme i nethinden, skal lægen efter at have rådspurgt en specialist afgøre, om det er nødvendigt, at De får langtidsbehandling med <lægemidler, der indeholder tranexamsyre> injektionsvæske. 
With pathological ophthalmic changes, particularly with diseases of the retina, your doctor must take a decision after consulting a specialist on the necessity for the long-term use of <Tranexamic acid-containing medicinal products> solution for injection in your case.
• Tranexamsyre må ikke gives intramuskulært 
• Tranexamic acid should not be administered by the intramuscular route.
Administration af tranexamsyre ved DIC bør kun overvejes, hvis passende hæmatologiske laboratoriefaciliteter og ekspertise er tilgængelig. 
In such acute cases a single dose of 1g tranexamic acid is frequently sufficient to control bleeding.. Administration of Tranexamic acid in DIC should be considered only when appropriate haematological laboratory facilities and expertise are available.
4.7 Virkning på evnen til at føre motorkøretøj eller betjene maskiner 
4.7 Effects on ability to drive and use machines No studies have been performed on the ability to drive and use machines.
Fibrinolytiske forhold som følge af dissemineret intravaskulær koagulation undtagen tilfælde med overvejende aktivering af det fibrinolytiske system med akut alvorlig blødning (se pkt. 
Acute venous or arterial thrombosis (see section 4.4 Special) Fibrinolytic conditions following consumption coagulopathy except in those with predominant activation of the fibrinolytic system with acute severe bleeding (see section 4.4) Severe renal impairment (risk of accumulation)
• oral prævention (P-piller) 
• oral contraceptives
Det er ikke undersøgt, om tranexamsyre påvirker evnen til at føre motorkøretøj eller betjene maskiner. 
Driving and using machines No studies have been performed on the ability to drive and use machines.
Hvis De er gravid eller ammer, skal De spørge Deres læge til råds, før De tager <lægemidler, der indeholder tranexamsyre>. 
Ask your doctor for advice if you are pregnant or breast-feeding before taking <Tranexamic acidcontaining medicinal products>.
Standardbehandling ved generel fibrinolyse: 1 g (1 ampul med 10 ml eller 2 ampuller med 5 ml) tranexamsyre som langsom intravenøs injektion (= 1 ml/min.) 
Standard treatment of general fibrinolysis: 1 g (1 ampule of 10 ml or 2 ampules of 5 ml) tranexamic acid by slow intravenous injection (= 1 ml/minute) every 6 to 8 hours, equivalent to 15 mg/kg BW
- Kramper især i forbindelse med forkert anvendelse (se pkt. 
- Convulsions particularly in case of misuse (refer to sections 4.3 and
Fortæl det til lægen, hvis noget af følgende gælder for Dem, da det vil hjælpe lægen med at afgøre, om De skal have <lægemidler, der indeholder tranexamsyre>: 
Warnings and precautions Tell your doctor if any of these apply to you to help him or her decide if <Tranexamic acidcontaining medicinal products> is suitable for you:
Nedsat leverfunktion Dosisnedsættelse er ikke nødvendig. 
Use in patients with hepatic impairment No reduction in dosage is necessary.
Brug af anden medicin sammen med <lægemidler, der indeholder tranexamsyre> Fortæl altid lægen eller på apoteket, hvis De tager anden medicin eller har gjort det for nylig. 
Other medicines and <Tranexamic acid - containing medicinal products> Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription, vitamins, minerals, herbal medicines or dietary supplements.
Hos 17 patienter, der gennemgik knæoperation, var koncentrationen i ledvæsken den samme som i tilsvarende serumprøver, efter en intravenøs injektion på 10 mg/kg. 
Following administration of an intravenous injection of 10 mg/kg to 17 patients undergoing knee surgery, concentrations in the joint fluids were similar to those seen in corresponding serum samples.
Nedsat leverfunktion Dosisjustering er ikke nødvendig til patienter med nedsat leverfunktion. 
Hepatic impairment No dose adjustment is required in patient with hepatic impairment.
Bivirkninger 
Undesirable Effects
De vil få <lægemidler, der indeholder tranexamsyre> injektionsvæske, som en langsom injektion i en blodåre. 
How to take Use in Adults <Tranexamic acid - containing medicinal products>solution for injection will be given to you by slow injection into a vein.
4.3 og 4.4) 
1.35 to 2.82
Følgende bivirkninger er set efter behandling med <lægemidler, der indeholder tranexamsyre>: 
Side effects reported with <Tranexamic acid - containing medicinal products> are: The following side effects have been observed with <Tranexamic acid - containing medicinal products>
Akut venetrombose eller arteriel trombose (se pkt. 
- Arterial or venous thrombosis at any sites
• Thoraxkirurgi og abdominalkirurgi og andre større kirurgiske indgreb, f.eks. kardiovaskulær kirurgi 
- Haemorrhagic urinary disorders, further to prostate surgery or surgical procedures affecting the urinary tract, - Ear Nose Throat surgery (adenoidectomy, tonsillectomy, dental extractions), - Gynaecological surgery or disorders of obstetric origin, - Thoracic and abdominal surgery and other major surgical intervention such as cardiovascular surgery, - Management of haemorrhage due to the administration of a fibrinolytic agent.
Det frarådes at anvende <lægemidler, der indeholder tranexamsyre>, hvis De ammer. 
Therefore, the use of <Tranexamic acid - containing medicinal products> during breast-feeding is not recommended.
Denne indlægsseddel blev senest ændret [Udfyldes nationalt] 
This leaflet was last revised in <{MM/YYYY}> <{month YYYY}>.
Det skal De vide, før De får <lægemidler, der indeholder tranexamsyre> Sådan bliver De behandlet med <lægemidler, der indeholder tranexamsyre> Bivirkninger 
What you need to know before you are given <Tranexamic acid - containing medicinal products>
Oversigt over indlægssedlen 
SUMMARY OF PRODUCT CHARACTERISTICS
Bivirkning 
Possible side Effects
2-3 gange dagligt 2. 
250 to 500
Indlægsseddel: Information til patienten <Lægemidler, der indeholder tranexamsyre> 
PACKAGE LEAFLET Package leaflet: Information for the patient
Sådan bliver De behandlet med <lægemidler, der indeholder tranexamsyre> Voksne 
How to store <Tranexamic acid - containing medicinal products>
Tranexamsyre er kontraindiceret hos patienter med alvorligt nedsat nyrefunktion pga. risiko for akkumulering (se pkt. 
In renal insufficiency leading to a risk of accumulation, the use of tranexamic acid is contraindicated in patient with severe renal impairment (see section 4.3).
Dosis til børn over 1 år ved de godkendte indikationer, som er beskrevet i pkt. 
In children from 1 year, for current approved indications as described in section 4.1, the dosage is in the region of 20 mg/kg/day.
• Blødning forårsaget af generel eller lokal fibrinolyse, f.eks. o Menoragi og metroragi o Gastrointestinal blødning o Hæmoragiske urinvejssygdomme i fortsættelse af prostatakirurgi eller kirurgiske indgreb i urinvejene 
Specific indications include: - Heavy periods in women - Gastrointestinal bleeding - Haemorrhagic urinary disorders, further to prostate surgery or surgical procedures affecting the urinary tract - Ear, nose, or throat surgery heart, abdominal, or gynecological surgery bleeding after you have been treated with another medicine to break down blood clots.
(dissemineret intravaskulær koagulation) er <lægemidler, der indeholder tranexamsyre> 
<Tranexamic acid - containing medicinal products>
Pakningsstørrelser og yderligere oplysninger <Lægemidler, der indeholder tranexamsyre> indeholder: [Udfyldes nationalt] 
What <Tranexamic acid - containing medicinal products> <Tranexamic acid - containing medicinal products> is and what it is used for
• tidligere har haft kramper. 
• have a history of convulsions.
Undtaget er tilfælde, hvor De har akut alvorlig blødning og blodprøver har vist, at den mekanisme, der nedsætter blodets evne til at størkne (fibrinolyse), er aktiveret. 
• If you have excessive clotting or bleeding throughout your body (disseminated intravascular coagulation), <Tranexamic acid - containing medicinal products> may not be right for you, except if you have acute severe bleeding and blood test have shown the process that inhibits blood clotting called fibrinolysis is activated.
Opbevaring [Udfyldes nationalt] 
[To be completed nationally]
112 tabletter 
112 tablets
200 mg Tablet, filmovertrukket 
200 mg Film-coated tablet
Brug ikke kemiske desinfektionsmidler. 
Do not use chemical disinfectants.
DATO FOR FØRSTE TILLADELSE/FORNYELSE AF TILLADELSEN Dato for første markedsføringstilladelse: 03/07/2015 
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 03/07/2015
Bovint serum Basalmedium Dimethylsulfoxid 
Bovine serum Basal medium Dimethyl sulfoxide
MARKEDSFØRINGSTILLADELSENS NUMMER (NUMRE) EU/2/15/182/001 
MARKETING AUTHORISATION NUMBER(S) EU/2/15/182/001
Det er vigtigt, at suspensionen, efter at være blevet optøet, straks blandes i solvensen for at beskytte cellerne. 
It is important that the suspension, after being thawed, is mixed immediately into the solvent to protect the cells.
Desinficér vaccinationsudstyret ved at koge det i vand i 20 minutter eller ved autoklavering (15 minutter ved 121 °C). 
Disinfect vaccinating equipment by boiling in water for 20 minutes or by autoclaving (15 minutes at 121 °C).
MÆNGDEN AF AKTIVT STOF (AKTIVE STOFFER) HVT/ILT-138 
QUANTITY OF THE ACTIVE SUBSTANCE(S) HVT/ILT-138
TEKSTEN ”TIL DYR” For animal treatment only. 
THE WORDS “FOR ANIMAL TREATMENT ONLY” For animal treatment only.
Enhver, som har til hensigt at fremstille, indføre, besidde, sælge, levere og/eller anvende Innovax-ILT, skal rådføre sig med det relevante medlemslands kompetente myndighed vedrørende gældende vaccinationspolitik forinden fremstilling, indførsel, besiddelse, salg, levering og/eller anvendelse finder sted. 
Any person intending to manufacture, import, possess, sell, supply and/or use Innovax-ILT must consult the relevant Member State's competent authority on the current vaccination policies prior to the manufacture, import, possession, sale, supply and/or use.
Vaccinen administreres ved subkutan injektion i nakken. 
The vaccine is administered by subcutaneous injection in the neck.
Yderligere information om dette lægemiddel er tilgængelig på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu. 
Detailed information on this product is available on the website of the European Medicines Agency: (http://www.ema.europa.eu/).
Må ikke blandes med andre lægemidler til dyr, undtagen Nobilis Rismavac og den solvens, der leveres til brug sammen med dette veterinærlægemiddel. 
Do not mix with any other veterinary medicinal product except Nobilis Rismavac and the solvent supplied for use with the veterinary medicinal product.
Immunitetens varighed: ILT: 60 uger, MD: hele risikoperioden. 
Duration of immunity: ILT: 60 weeks, MD: entire risk period.
Ved subkutan vaccination bør der drages omsorg for at undgå beskadigelse af blodkarrene på halsen af kyllingerne. 
During subcutaneous vaccination, care should be taken to prevent damage of the blood vessels in the neck of the chickens.
Fremstilling, indførsel, besiddelse, salg, levering og/eller anvendelse af Innovax-ILT kan være forbudt i et medlemsland på hele eller en del af medlemslandets område i henhold til national lovgivning. 
The manufacture, import, possession, sale, supply and/or use of Innovax-ILT may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.
ADVARSEL: Det er i nogle tilfælde set, at ampuller er eksploderet ved pludselige temperaturændringer. 
CAUTION: Ampoules have been known to explode on sudden temperature changes.
Der er ikke observeret nogen symptomer efter administration af 10 gange normal vaccinedosis. 
No symptoms were observed after the administration of a 10-fold dose of vaccine.
Overdosis (symptomer, nødforanstaltninger, modgift): Der er ikke observeret nogen symptomer efter administration af 10 gange normal vaccinedosis. 
Overdose (symptoms, emergency procedures, antidotes): No symptoms were observed after the administration of a 10-fold dose of vaccine.
Der foreligger data vedrørende sikkerhed og virkning, som viser, at denne vaccine kan gives samme dag som, men ikke blandet med Nobilis ND Clone 30 eller Nobilis ND C2. 
Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day, but not mixed with, Nobilis ND Clone 30 or Nobilis ND C2.
Suspension: - Type I-glasampuller, der indeholder 2.000 eller 4.000 doser. 
Suspension: - Type I glass ampoules containing 2,000 or 4,000 doses.
INDGIVELSESVEJ(E) Læs indlægssedlen inden brug. 
ROUTE(S) OF ADMINISTRATION Read package leaflet before use.
BILAG II A. FREMSTILLER AF DE BIOLOGISK AKTIVE STOFFER OG FREMSTILLER ANSVARLIG FOR BATCHFRIGIVELSE B. BETINGELSER ELLER BEGRÆNSNINGER FOR MARKEDSFØRINGSTILLADELSEN VEDRØRENDE UDLEVERING OG BRUG C. ANGIVELSE AF MRL-VÆRDIER D. ANDRE FORHOLD OG BETINGELSER FOR MARKEDSFØRINGSTILLADELSEN 
ANNEX II A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCES AND> MANUFACTURER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. STATEMENT OF THE MRLs D. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
Når dette produkt blandes med Nobilis Rismavac, bør begge fortyndes i samme pose med solvens på samme måde (400 ml solvens for hver 2.000 doser af begge produkter eller 800 ml solvens for hver 4.000 doser af begge produkter). 
When this product is mixed with Nobilis Rismavac, both should be diluted in the same solvent bag in the same way (400 ml of solvent for each 2,000 doses of both products or 800 ml of solvent for each 4,000 doses of both products).
Når Innovax-ILT blandes med Nobilis Rismavac, kan udviklingen af immunitet mod ILT være forsinket hos dyr med maternelt overførte antistoffer. 
When Innovax-ILT is mixed with Nobilis Rismavac the development of immunity towards ILT may be delayed in animals with maternally derived antibodies.
Efter at have tilsat indholdet af ampullen til solvensen, er det klargjorte produkt en klar, rødfarvet suspension til injektion. 
After adding the content of the ampoule to the solvent, the ready to use product is a clear, red coloured suspension for injection.
Der bør træffes passende foranstaltninger for at undgå at udsætte hænder, øjne og tøj for kontakt med suspensionen. 
Care should be exercised to prevent contaminating your hands, eyes and clothing with the suspension.
1 PFU: plaquedannende enheder. 
1 PFU: plaque forming units.
Da det er en levende vaccine, udskilles vaccinestammen fra vaccinerede fugle og kan spredes til kalkuner. 
As a live vaccine, the vaccine strain is excreted from vaccinated birds and may spread to turkeys.
Anvend solvens (Solvens til celleassocierede hønsevacciner) til rekonstitution. 
Use solvent (Solvent for cell associated poultry vaccines) for reconstitution.
Fertilitet: Der foreligger ingen oplysninger vedrørende anvendelse til kommende ynglende fugle. 
Fertility: No information is available on use in future breeding birds.
Særlige advarsler for hver dyreart: Vaccinér kun raske daggamle kyllinger. 
Special warnings for each target species: Vaccinate healthy one-day-old chicks only.
Ampullerne må derfor ikke optøs i varmt eller iskoldt vand. 
Do not thaw in hot or ice cold water.
VETERINÆRLÆGEMIDLETS NAVN Innovax-ILT 
NAME OF THE VETERINARY MEDICINAL PRODUCT Innovax-ILT
Der foreligger ingen oplysninger vedrørende anvendelse til kommende ynglende fugle. 
No information is available on use in future breeding birds.
KVALITATIV OG KVANTITATIV SAMMENSÆTNING En dosis (0,2 ml) rekonstitueret vaccine indeholder: 
QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose (0.2 ml) of reconstituted vaccine contains:
Træk en portion solvens op i sprøjten for at skylle ampullen. 
Withdraw a portion of the solvent into the syringe to rinse the ampoule.
DOSERING FOR HVER DYREART, ANVENDELSESMÅDE OG INDGIVELSESVEJ Efter fortynding administreres 1 dosis på 0,2 ml vaccine pr. kylling ved subkutan injektion i nakken. 
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION After dilution, administer 1 dose of 0.2 ml of vaccine per chicken by subcutaneous injection in the neck.
Posen med vaccine bør forsigtigt roteres gentagne gange under vaccinationen for at sikre vaccinesuspensionen forbliver homogen og at den korrekte vaccinevirus titer indgives (f.eks. ved vaccinationer af længere varighed). 
The bag of vaccine should be gently swirled frequently during vaccination to guarantee that the vaccine suspension remains homogenous and that the correct vaccine virus titre is administered (e.g. during long vaccination sessions).
Der foreligger oplysninger om sikkerhed og virkning, som viser, at Innovax-ILT kan blandes i samme solvens og gives sammen med Nobilis Rismavac i medlemslande, hvor denne vaccine er godkendt. 
Safety and efficacy data are available which demonstrate that Innovax-ILT can be mixed in the same solvent and administered with Nobilis Rismavac in Member States where this vaccine is authorized.
PFU: plaquedannende enheder. 
PFU: plaque forming units.
Dosering: En enkelt injektion på 0,2 ml pr. kylling, som er en dag gammel, subkutant. 
Posology: One single injection of 0.2 ml per chick at the age of one day, by the subcutaneous route.
VETERINÆRLÆGEMIDLETS NAVN Solvens til celleassocierede hønsevacciner 
NAME OF THE VETERINARY MEDICINAL PRODUCT Solvent for cell associated poultry vaccines
Såfremt denne blanding anvendes, er det for MD påvist, at immunitet indtræder efter 5 dage. 
For this mixed use, an onset of immunity of 5 days has been demonstrated for MD.
Innovax-ILT er en virussuspension, som leveres i glasampuller, der opbevares i flydende kvælstof. 
Innovax-ILT is a virus suspension packed in glass ampoules and stored in liquid nitrogen.
Anvend 400 ml solvens for hver 2.000 doser cellesuspension eller 800 ml solvens for hver 4.000 doser cellesuspension. 
Use 400 ml of solvent for each 2,000 doses of cell suspension or 800 ml of solvent for each 4,000 doses of cell suspension.
Opbevaringstid efter rekonstituering ifølge anvisning: 2 timer ved en temperatur under 25 °C. 
Shelf life after reconstitution according to directions: 2 hours at a temperature below 25 °C.
Stik kanylen gennem proppen på posen med solvens, og tilsæt langsomt og forsigtigt indholdet af sprøjten til solvensen. 
Insert the needle through the stopper of the solvent bag and add slowly and gently the contents of the syringe to the solvent.
Immunitetens indtræden: ILT: 4 uger, MD: 9 dage. 
ILT: 4 weeks, MD: 9 days.
5 poser med 400 ml solvens eller 5 poser med 800 ml solvens. 
5 bags of 400 ml solvent or 5 bags of 800 ml solvent.
Kyllinger 
Chickens.
Opbevares og transporteres nedfrosset i flydende kvælstof (-196 °C). 
Store and transport frozen in liquid nitrogen (-196 °C).
Cellesuspension: Opbevares og transporteres nedfrosset i flydende kvælstof (-196 °C). 
Cell suspension: Store and transport frozen in liquid nitrogen (-196 °C).
De skal optøs i rent vand ved 25-27 °C. 
For this reason, thaw the ampoules in clean water at 25-27 °C.
I tilfælde af uheld er det vigtigt at forebygge risikoen for alvorlige sår på grund af flydende kvælstof eller ampullerne; når en ampul tages op af beholderen, skal den derfor holdes i håndfladen iført handske væk fra krop og ansigt. 
In case of an accident to prevent serious wounds by either the liquid nitrogen or the ampoules when removing an ampoule from the canister, hold palm of gloved hand away from body and face.
Vaccinen stimulerer aktiv immunitet mod infektiøs laryngotracheitis og Marek's disease hos kyllinger. 
The vaccine induces active immunity against infectious laryngotracheitis and Marek's disease in chickens.
antal ampuller optøs hurtigt ved nedsænkning i rent vand ved 25-27 °C. 
The content of the ampoule(s) is thawed rapidly by immersing in clean water at 25-27 °C.
Fastgjort på staven er en farvet klemme som viser antal doser (2.000 doser: lakse-pink farvet klemme og 4.000 doser: Gul farvet klemme). 
Five ampoules per cane, attached to the cane is a coloured clip displaying the dose (2,000 doses: salmon-pink coloured clip, and 4,000 doses: yellow coloured clip).
VETERINÆRLÆGEMIDLETS NAVN Innovax-ILT, suspension og solvens til injektionsvæske, suspension, til kyllinger 
NAME OF THE VETERINARY MEDICINAL PRODUCT Innovax-ILT, suspension and solvent for suspension for injection for chickens
INDLÆGSSEDDEL: Innovax-ILT, suspension og solvens til injektionsvæske, suspension, til kyllinger 
PACKAGE LEAFLET: Innovax-ILT suspension and solvent for suspension for injection for chickens
Opbevaringstid for cellesuspension i salgspakning: 3 år. 
Shelf life of the cell suspension as packaged for sale: 3 years.